# Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

> **NCT02457598** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 203 (actual)

## Conditions studied

- B-cell Malignancies

## Interventions

- **DRUG:** Tirabrutinib
- **DRUG:** Idelalisib
- **DRUG:** Entospletinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT02457598
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-16
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 203 (ACTUAL)
- **Why stopped:** The goal of the study was to improve tolerability while maintaining or increasing efficacy. The results of this study showed no efficacy advantage although the combinations were well tolerated.
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02457598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02457598, "Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02457598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*